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a b s t r a c t
Anal cancer is relatively rare; however, its incidence has increased in recent years. Several
risk factors are associated with the development of anal cancer, including age older than
50 years, low-ﬁber diet, chronic anal ﬁstulas, smoking, multiple partners, anal intercourse
practice, Human Immunodeﬁciency Virus infection and immunosuppression. However, the
presence of human papillomavirus represents the main risk factor for the development of
anal cancer. The aim of this study was to evaluate the clinicopathological aspects of a series
of patients with anal carcinomas diagnosed in Hospital Araújo Jorge, Goiânia-Goiás, as well
as the prevalence of human papillomavirus genome in these tumors. Clinical, pathological
and socio-demographic data were collected from the respective medical ﬁles and parafﬁn
blocks containing anal carcinomas specimens were used for DNA extraction and detection
of human papillomavirus, by means of polymerase chain reaction, using short PCR fragment
primers. Forty-three cases were selected and had the data analyzed, while 38 cases were
tested for human papillomavirus genome detection. Among the evaluated patients, 62.8%
were women; 53.4% of tumors were squamous cell carcinoma and 46.5% of the patients
were aged between 60 and 75 years. Risk factors, such as smoking (39.5%) and alcoholism
(20.9%) were recorded in the studied group. Lymph node metastases were detected in 30.2%
of cases and 7.0% had distant metastasis. The detection of human papillomavirus DNA
was positive in 76% of cases assessed and this was signiﬁcantly associated with squamous
cell carcinomas. Aggressive behavior and advanced stage of anal cancer described in this
study highlight the need for preventive measures that contemplate these tumors, including
vaccination against human papillomavirus.© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda.
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Aspectos clínico-patológicos e prevalência do papilomavírus humano
(HPV) em carcinomas anais
Palavras-chave:
Câncer anal
Características
Papilomavirus humano
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HPV16
HPV18
r e s u m o
O câncer anal é relativamente raro, entretanto, sua incidência aumentou nos últimos anos.
Vários fatores de risco são associados ao desenvolvimento do câncer anal, incluindo idade
maior que 50 anos, dieta pobre em ﬁbras, fístulas anais crônicas, tabagismo, múltiplos
parceiros, prática de intercurso anal, infecc¸ão pelo HIV e imunossupressão. Entretanto,
a presenc¸a do Papilomavírus Humano (HPV) representa o principal fator de risco para o
desenvolvimento do câncer anal. O objetivo deste estudo consistiu em avaliar os aspectos
clínico-patológicos de uma série de pacientes comcarcinomas anais diagnosticados noHos-
pital Araújo Jorge, Goiânia/GO, bem como a prevalência do genoma do HPV nesses tumores.
Dados clínico-patológicos e sóciodemográﬁcos foram colhidos a partir dos respectivos pron-
tuários e blocos de paraﬁna contendo espécimes de carcinomas anais foram usados para
extrac¸ão de DNA e detecc¸ão de HPV, por meio da reac¸ão em cadeia da polimerase, usando
oligonucleotídeos iniciadores SPF. Quarenta e três casos foram selecionados e tiveram os
dados clinico-patológicos analisados, enquanto 38 casos foram testados para a detecc¸ão do
genoma do HPV. Dentre os pacientes avaliados, 62,8% eram mulheres; 53,4% dos tumores
eram carcinomas de células escamosas e 46,5% dos pacientes estavam na faixa etária entre
os 60 e 75 anos. Fatores de risco, como tabagismo (39,5%) e etilismo (20,9%) foram registra-
dos no grupo estudado. Metástases linfonodais foram detectadas em 30,2% dos casos e 7,0%
apresentaram metástase à distância. A detecc¸ão de HPV foi positiva em 76,0% dos casos
analisados e este signiﬁcativamente associado aos carcinomas de células escamosas. O
comportamento agressivo e o estágio avanc¸ado dos carcinomas anais descritos no presente
estudo destacam a necessidade de medidas de prevenc¸ão que contemplem esses tumores,
incluindo a vacinac¸ão contra o HPV.
© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
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nal cancer is relatively rare, accounting for about 30,000
ew cases a year worldwide, with a peak incidence between
he ages of 58 and 64 years.1 It represents approximately
.5% of all tumors of the digestive tract and 2–3% of colorec-
al tumors.2 However, its incidence has increased in recent
ears.3 In the U.S., an incidence of 1.6 cases/100,000 inhabi-
ants was reported in the period 2002–2006.1
Anal tumors can occur in the anal verge or in the anal
anal, up to the transition to the rectum. Tumors that arise
n the anal verge are dermatological lesions and as such, can
e treated with local excision. On the other hand, tumors
hat arise in the anal canal or in the transition zone of the
nal canal with the rectum deserve a more aggressive surgical
pproach.4
Anal carcinomas have a wide histological variety. Tumors
hat appear distal to the pectineal line, the border between
he anal canal and the rectum, are keratinized squamous
ell carcinomas, also called epidermoid carcinomas. The non-
eratinized squamous cells carcinomas are located above the
ectineal line and are called epithelioid carcinomas. There
re other histological types, such as adenocarcinomas (ADC),
ransitional cell or cloacogenic tumors, basaloid and mucus-
pithelioid tumors. The epidermoid carcinoma is the most
ommon cancer of the anus and is responsible for 85% of
alignant lesions of this region.4–6The clinical presentation and severity of anal cancers
depend on the size and location of the tumor in the anus.
Small, mobile lesions, smaller than 2 cm have a probability of
cure in 80% of cases, compared with <50% chance for tumors
larger than 5 cm. It is known that 20% of patients are asymp-
tomatic; however, anal bleeding and the sensation of a mass
occupying the anal canal are the most frequent signs and
symptoms, often mistakenly associated with hemorrhoidal
disease.4,6
The treatment of anal carcinoma can be surgical and clin-
ical. Surgical treatment is based on local excision of the
lesion or abdominoperineal resection of the rectum and anus,
whereas the medical treatment is based on the anorectal
segment preservation through chemoradiotherapy or radio-
therapy alone.4
Tumors of the anal canal are more common in females,
while anal margin tumors are more frequent in males.7 Some
studies have shown that although the prevalence of anal can-
cer is higher in women older than 60 years of age, the disease
has become very common in men between 30 and 40 years,
due to high association with infection by the Human Immu-
nodeﬁciency Virus (HIV).1
Several risk factors are known to be associated with the
development of anal cancer, including age older than 50 years,
Este é um artigo Open Access sob a licença de CC BY-NC-NDlow-ﬁber diet, chronic anal ﬁstulas, smoking, multiple part-
ners, history of anal intercourse (receptive anal sex), HIV
infection, immunosuppression following organ transplanta-
tion and immunosuppressive drugs. However, the presence of
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humanpapillomavirus (HPV) shows themain associationwith
the development of anal cancer.2,8
HPVs are small double-strandedDNAviruses,whichbelong
to the Papillomaviridae family. Initially, these viruseswere iden-
tiﬁed, cloned and sequenced from samples of cervical tumors,
and subsequently established as important etiological agents
of carcinogenesis in several human tumors.9,10 More than 200
types of HPV have been identiﬁed and each of them has par-
ticular tropism for speciﬁc anatomical sites.11
HPV infection seems to be associated with the majority
of anal tumors, especially with squamous cell carcinomas.
Among the genotypes most frequently associated with anal
tumors, HPV 16 and HPV 18 are considered as high risk for the
development of anal cancer. The overall percentage of anal
cancers attributed to HPV is 90%, especially for genotypes 16
and 18, which correspond to 92% of cases, with some differ-
ences depending on the geographic region (75% in men× 91%
in women). HPV 16 is the most prevalent type, found in over
70% of cases.1,9
The constant practice of receptive anal sex apparently
contributes to a higher frequency of anal lesions and also rep-
resents one of the main factors for the acquisition of HIV and
HPV coinfection, important risk factors for anal intraepithelial
neoplasia (AIN), considered the precursor lesion of anal squa-
mous carcinoma. It is believed that the HIV virus is a cofactor
that HPV needs to induce neoplasms that can progress to anal
carcinoma.2
Objectives
The aim of this study was to evaluate the clinical, pathological
and sociodemographic characteristics of patients diagnosed
with anal carcinoma in Hospital Araújo Jorge, Goiânia/GO, in
the period 2004–2011, aswell as the prevalence of HPV genome
in these tumors.
Methods
Study type and sample
The study consisted of an epidemiological investigation that
used clinicopathological data collected from medical records
and analysis of parafﬁn blocks containing specimens of anal
carcinomas. The study was approved by the Ethics Commit-
tee on Human Research of Hospital Araújo Jorge (HAJ), under
number 272 288 inApril 2013. As thiswas a retrospective study,
there was no direct contact with selected patients and thus, it
did not require the signing of the free and informed consent
form. The prevalence of HPV was investigated in 43 specimens
of anal carcinomas diagnosed in HAJ, in Goiânia/GO, in the
period 2004–2011.
Patients included in the study were those with conﬁrmed
histopathological diagnosis of anal carcinoma and clinico-
pathological data available in their medical records. The
detection of HPV included the cases in which the paraf-
ﬁn blocks were sufﬁcient and were available for molecular
analysis. Case selection was made from an active search
of the records of the Department of Pathology of HAJ.
The slides stained with hematoxylin–eosin related to each014;34(2):76–82
anatomopathological examination were reviewed and sec-
tions were prepared for DNA extraction.
DNA extraction
Genomic DNA was puriﬁed from tumor samples ﬁxed in
formalin and embedded in parafﬁn, according to standard pro-
tocols used in the Laboratory of Genetic Diversity of Pontifícia
Universidade Católica Goiás (PUC Goiás). The deparafﬁniza-
tion and hydration steps were performed and DNA extraction
and puriﬁcation were performed using a commercial Wizard
Kit (Promega). All puriﬁed DNA samples were tested for qual-
ity and integrity via ampliﬁcation of a fragment of constitutive
BRAF gene of 224bp.
Detection of HPV genome in tumor samples
Detection of HPV DNA was performed by polymerase chain
reaction (PCR) using SPF primers,12 which amplify a fragment
of 75 base pairs of the viral genome and developed to promote
sensitive ampliﬁcation of the most clinically relevant HPV
genotypes. The assay is capable of detecting the genotypes
currently known as high risk HPVs (16, 18, 26, 31, 33, 35, 39, 45,
51, 52, 53, 56, 58, 59, 66, 68, 73 e 82), as well as low-risk HPV
genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types.
HPV detection was performed at the Laboratory of Bone
Marrow Transplantation of Associac¸ão de Combate ao Câncer
in Goiás and Laboratory of Genetic Diversity of PUC-Goiás. The
PCRwithSPFprimerswasperformed in aﬁnal reactionvolume
of 25L, containing 2L of puriﬁed DNA, 10mmol/L Tris–HCl,
pH 9.0, 50mmol/L KCl, 2.5mmol/L MgCl2 200mmol/L each
of deoxy-nucleotide (dNTP), 10pmol of each oligonucleotide
primer, and 0.25U of Taq Polymerase (Invitrogen, Brazil). The
cycling conditions included: preheating for 1min at 94 ◦C fol-
lowed by 40 cycles of 1min at 94 ◦C, 1min at 45 ◦C and 1min
at 72 ◦C, with a ﬁnal extension of 5min at 72 ◦C.
EachPCRexperimentwasperformedwithpositive andneg-
ative controls, previously tested in the Laboratory of Genetic
Diversity of PUC-Goiás. A fragment of human BRAF gene with
224bp was ampliﬁed from DNA extracted from each sample
to conﬁrm the presence and the capacity of amplifying the
extracted DNA from each sample.
Statistical analyses
Thedata obtainedwere codedand stored in adatabase in Excel
software program and analyzed using GraphPad Prism. Clini-
copathological and sociodemographic data were processed to
descriptive statistical analysis and the data on HPV detection
regarding the different variables were analyzed using Fisher’s
exact test and Chi-square test, considering statistically signif-
icant differences the ones that resulted in p value≤ 0.05.
ResultsClinicopathological and sociodemographic characteristics
A group of 55 cases of anal carcinomas was initially selected,
but 12 of them were excluded from the analysis because three
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Table 1 – Descriptive analysis of the sociodemographic
characteristics of the study group.
Variable N %
Gender
Female 27 62.8
Male 16 37.2
Age at diagnosis (years)
31–45 5 11.6
46–60 13 30.2
61–75 20 46.5
>75 5 11.6
Marital status
Single 8 18.6
Married 17 39.5
Widowed 9 20.9
Separated 4 9.3
Common-law marriage 4 9.3
Not informed 1 2.3
Ethnicity
White 17 39.5
Biracial 23 53.5
Black 2 4.7
Non-speciﬁed 1 2.3
Smoker
Yes 17 39.5
No 20 46.5
Not informed 6 14.0
Alcohol consumption
Yes 9 20.9
No 26 60.5
Not informed 8 18.6
Origin
Greater Goiânia area 20 46.5
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Table 2 – Descriptive analysis of clinicopathological
characteristics of the study group.
Variable N %
Histological type
SCC 23 53.5
Adenocarcinoma 16 37.2
Basaloid/cloacogenic carcinoma 3 7.0
Neuroendocrine 1 2.3
Diagnostic method
Biopsy 25 58.1
Surgery 18 41.9
Treatment
Surgery 33 76.7
Radiotherapy 28 65.1
Chemotherapy 28 65.1
No treatment 2 4.7
Lymph node metastasis
Yes 13 30.2
No 30 69.8
Distant metastases
Yes 3 7.0
No 40 93.0
Sites of distant metastases
Liver 1 25
Lung 2 50
Brain 1 25
Death record
Yes 11 25.5
No 32 74.4
in recent years. The present study analyzes a retro-Other cities in the state of Goiás 19 44.2
Other states 4 9.3
ases received chemotherapy/radiotherapy before surgery
nd nine were colorectal ADCs extending to the anus. The
emaining 43 caseswere evaluated regarding clinicopathologi-
al and sociodemographic characteristics,which are described
nTables 1 and 2. All datawere collected throughmedical chart
eview at HAJ.
Of the assessed patients, 62.8% were females. Approx-
mately half of the sample (53.5%) was diagnosed with
quamous cell carcinoma (SCC), while 37.2% were ADCs. Most
atients (46.5%) were aged between 61 and 75 years and 39.5%
ere married. Risk factors such as smoking (39.5%) and alco-
ol consumption (20.9%) were recorded in the study sample.
ata associated with sexual behavior and orientation, such as
he number of partners, age at the ﬁrst sexual intercourse and
ractice of receptive anal sex were not reported in the medical
ecords.
In 63.2% of cases, the diagnosis was made by biopsy. The
reatment chosen for the group was, in general, a combina-
ion of surgery, chemotherapy and radiotherapy, with 76.7%
f patients being submitted to surgery. Lymph node metas-
ases were detected in 13 patients (30.2%) and four (9.3%) had
istant metastasis, with the lungs being the most prevalent
ite (50.0%). Although all patients were not followed for a
ong period of time, at the end of the data collection period,SCC, squamous cell carcinoma.
11 patients had their deaths recorded in their medical ﬁles
(25.6%).
HPV detection in anal carcinoma samples
Of the 43 samples initially evaluated, 38 had parafﬁn-
embedded histopathological specimens available and sufﬁ-
cient for DNA extraction. All these samples were previously
tested for endogenous control ampliﬁcation, the human BRAF
gene and provided DNA suitable for PCR ampliﬁcation. Of the
38 samples, 29 were positive for detection of HPV DNA (76.3%).
Differences between HPV(+) and HPV(−) tumors in relation to
sociodemographic and clinicopathological features were eval-
uated and are described in Table 3. Signiﬁcant differences
(p=0.032) were observed in relation to SCCs and ADCs, con-
ﬁrming the association betweenHPV and anal SCCs. The other
variables investigated were not statistically signiﬁcant.
Discussion
Studies carried out in different countries are unanimous in
stating that, despite the fact that it is considered a rare
tumor, the incidence of anal cancer has increased steadily
1,13–15spective series of 43 patients with anal cancer diagnosed
in HAJ, in Goiânia-GO, in the period 2004–2011. The study
highlighted the clinical, pathological and sociodemographic
80 j coloproctol (rio j). 2014;34(2):76–82
Table 3 – Comparative analysis between the anal carcinomas HPV(+) and HPV(−).
HPV(+) (n=29) HPV(−) (n=9)
Variable N % N % p
Histological type
SCC 20 90.9 2 9.1
Adenocarcinoma 7 53.8 6 46.2 0.03218a
Other types 2 66.7 1 33.3
Diagnostic method
Biopsy 16 66.7 8 33.3
Surgery 13 92.9 1 7.1 0.1147
Lymph node metastasis
Yes 6 66.7 3 33.3
No 23 79.3 6 20.7 0.6553
Distant metastasis
Yes 5 62.5 3 37.5
No 24 80.0 6 20.0 0.3631
Death record
Yes 4 57.1 3 42.9
No 25 80.6 6 19.4 0.3225
Gender
Female 16 72.7 6 27.3
Male 13 81.2 3 18.8 0.7060
Marital status
Married 14 87.5 2 12.5
Others 15 68.2 7 31.8 0.2537
Smoker
Yes 14 87.5 2 12.5
No 12 66.7 6 33.3 0.2327
Not informed 3 75.0 1 25.0
Alcohol consumption
Yes 6 66.7 3 33.3
No 18 81.8 4 18.2 0.3841
Not informed 5 71.4 2 28.6
cinoma p≤ 0.05, statistically signiﬁcant difference; SCC, squamous cell car
characteristics of patients, as well as the detection of HPV
genome in the assessed tumor specimens. According to the
results of the series, 46.5% of the patients were aged 61–75
years. Different studies have reported that the most prevalent
age group for anal cancer is 50–70 years.13,14,16,17 The accu-
mulation of exposure to different risk factors throughout life
contributes to the higher prevalence of these tumors at older
ages.
A higher proportion of cases of anal carcinomas analyzed
in this serieswas detected inwomen (62.8%). This information
was previously reported by other authors;1,13,14,16–18 however,
plausible explanations for this observation are still inconclu-
sive. Several hypotheses have been suggested, such as that
women are more susceptible to HPV infection, by developing
HPV-related lesions in several anatomical sites, such as the
vulva, vagina and cervix and developing cervical cancer with
a very high frequency.14 Men also have frequent anogenital
HPV infection; however, the tumors associated with HPV are
signiﬁcantly less prevalent in males.
Our study showed that 39.5% of patients with anal cancer
were married; however, another signiﬁcant portion of patients
were widowed (20.9%) and single (18.6%), a factor that could
favor having a higher number of sexual partners. A highera.
proportion of married heterosexual men (72.2%) was also
found in the DALING study,13 which assessed anal cancer in
306 patients from the North-American west coast.
Although smoking is considered a major risk factor for anal
cancer, smokers did not represent the majority of cases in
our study; however, a signiﬁcant number reported smoking
(20.9%), and moreover, this information was not available in
many medical ﬁles (18.6%). Among the risk factors for anal
cancer, smoking is considered very signiﬁcant, both in women
and men.13
As it is a rare type of cancer, the total number of cases of
anal cancer analyzed in different series is, in general, small.
The study byAbramowitz et al.1 has the largest series,with 362
cases diagnosed in 16 anatomical pathology centers spread
throughout France. The second largest series13 analyzed 306
patients living in the state of Washington (USA) over a 12 year
period, 1986–1998. The histological type of anal cancer most
commonly associated to HPV infection is the SCC and, in this
study, we found this tumor type in 53.5% of the assessed sam-
ples.Our study evaluated the presence of the HPV genome in 38
cases of anal carcinoma and disclosed a prevalence of 76.3%.
A review of the association between HPV and anal carcinoma
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Table 4 – Studies that analyzed the prevalence of HPV in anal carcinomas.
Author/reference Country/region n HPV(+) (%) HPV 16(%) HPV 18(%)
Youk et al.20 Korea 21 100.0 100.0 –
Daling et al.13 Seattle, USA 306 88.0 73.0 6.9
Varnai el al.14 Germany 47 80.9 86.8 –
Kagawa et al.16 Japan 8 87.5 87.5 –
Tachezy et al.17 Czech Republic 27 70.4 100.0 –
Ramamoorthy et al.15 San Diego, USA 20 90.0 80.0 65.0
Abramowitz et al.1 France 362 96.0 75.7 5.8
Komlos et al.18 Slovenia 21 100.0 90.5 –
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tSoares et al.21 Brazil 33
as made by reviewing articles published in major biblio-
raphic databases (PubMed, SciELO, LILACS), using the terms
nal cancer, HPV PCR and selecting those published from 2000
n English or Portuguese languages. The search resulted in
ine selected studies and the results of HPV prevalence and
enotyping in the anal carcinomas are summarized in Table 4.
Molecular investigations on the detection of the HPV
enome in anal carcinomas indicate that anal cancer resem-
les cervical cancer in relation to HPV, that is, regarding
quamous carcinomas, HPV is considered the most important
isk factor for anal carcinogenesis.1,15
HPV infection is highly prevalent in patients with anal can-
er, being considered a necessary cause for anal squamous
ell carcinoma.19 In this study, an association between the
resence of HPV and anal squamous cells was observed, i.e.,
PV DNA was found in 90.9% of the SCCs. Some studies have
etected the viral genome in 100% of samples of anal squa-
ous cell carcinomas.18,20
However, in the largest series studied, the prevalence of
PV genome in anal carcinomas varied, ranging from 80.9%,14
8%13 and 96.7%.1 The different molecular methods used in
iral DNA detection in these tumors certainly explain this
iscrepancy. Our study used generic primers (FPS) capable of
mplifying a small fragment (75bp) of the HPV genome, allow-
ng the detection of viral DNA, even in samples of which DNA
ntegrity was not of excellent quality.
Similar to cervical cancer, anal cancer seems to occur in
he cells of the squamocolumnar junction, populated by a
ariety of precursor cells that originate different epithelia.17
tudies available in the literature show that anal carcinoma
arely occurs in the absence of HPV, reinforcing the role of the
irus as the main risk factor for this tumor type.1
Regarding the HPV subtypes in anal carcinomas, our study
id not include the analysis of present genotypes. According
o the available literature, a signiﬁcant predominance of HPV
6 is shown in relation to other genotypes in anal carcino-
as (Table 4). Youk et al.20 and Tachezy et al.17 detected the
resence of HPV 16 in 100% of the anal carcinoma samples
nalyzed. One explanation for this occurrence is that HPV 16
s closely involved in the development of anal SCC by promot-
ng changes in the genome still at the phase of micro-invasive
arcinoma, according to reports by Kagawa et al.16 in Japan.
HPV subtype 18 appears in global studies as the second
ost prevalent type of HPV in anal carcinomas, although the
ata are somewhat controversial. In nine studies found in
he literature (Table 4), the oncogenic potential of subtype 1860.6 42.4 15.2
is recognized in the natural history of anal carcinoma; how-
ever, only four studies performed HPV 18 genotyping in these
tumors.
In the study by Ramamoorthy et al.,15 carried out in San
Diego, USA, the prevalence of HPV subtype 18 was 65%,
whereas in the study by Daling et al.13 performed in Seattle,
HPV 18 was found in 6.9% of cases. In the study by Abramowitz
et al.,1 carried out in France, the prevalence of HPV subtype 18
was not greater than 5.8%.
The study by Soares et al.,21 carried out in Brazil, demon-
strated the presence of HPV 18 genome in 15.2% of cases.
This discrepancy may be related to HPV genotyping method,
as the molecular technologies used in the studies were
different.
Regarding the prognosis of patients with anal carcinoma,
data available in the literature are still very scarce. In the
present study, we observed a very aggressive behavior of these
tumors, with 13 patients (30.2%) showing lymph node metas-
tases and three patients (7.0%) with distant metastases: two
with lung metastases, one with liver metastasis and one with
brain metastasis. The aggressiveness of anal carcinoma can
also be observed by the number of deaths recorded during the
study period. Of the 43 patients included in the study, 11 died,
representing 25.6% of the study sample.
The increased incidence of anal carcinoma and knowl-
edge of the main factors involved in the etiology of these
tumors stimulate the need to develop preventive measures for
anal carcinoma. Suchmeasures include fullmedical examina-
tion, with an investigation of the sexual history of the patient
during anamnesis, careful clinical examination of the anogen-
ital region, detection of precursor lesions (intraepithelial anal
neoplasms), anoscopy and HPV vaccination, especially in the
higher-risk groups.16
High-risk patients include promiscuous individuals with a
high number of sexual partners, regular practice of anal inter-
course, low immunity (HIV, immunosuppressed individuals)
and past or current history of infection associated with anal
lesions (condylomas, cervical intraepithelial neoplasia (CIN),
vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial
neoplasia (VAIN) and vulvar, vaginal or cervical SCC). For this
group, clinical examination with anal inspection, perianal and
intra-anal cytology is recommended, as well as research of
HPV genome in samples of anal neoplasia.14The aggressive behavior and advanced stage of anal car-
cinomas observed in the present study highlight the need for
prevention campaigns, which also include vaccination against
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HPV. The studies by Abramowitz et al.1 in France and Kom-
los et al.18 in Slovenia emphasize the importance of further
studies on HPV vaccination in the prevention of anal can-
cer, as most of these tumors are signiﬁcantly associated with
HPV infection, particularly with HPV subtype 16. Vaccination
against high-risk HPV can have a big impact on the preva-
lence of anal carcinoma and its precursor lesions; however,
more detailed studies on its potential power to prevent such
tumors are still necessary.
This study has an important limitation regarding the col-
lection of clinical, pathological and behavioral data of the
patients. These data were scarce in most medical records,
including the practice of receptive anal intercourse, history
of HIV infection, presence of sexually transmitted diseases
(STDs) or condylomas, among others.
The studies by Daling et al.,13 in the USA and by
Abramowitz et al.,1 in France, also reported difﬁculties in
obtaining these samedata, both in interviews13 andduring the
review of medical ﬁles.1 Among the nine studies that evalu-
atedHPVdetection in anal carcinomas in the last 10 years, only
these two1,13 analyzed the risk factors for anal carcinoma, in
addition to HPV infection. The continuation of this study, with
the analysis of a greater number of cases of anal carcinomas
diagnosed in other oncology centers, as well as the genotyp-
ing of HPV in specimens of anal carcinomas is the objective of
our team.
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